Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library.

Small inhibitors of matrix metalloproteinase 12 (MMP-12) have been identified with a biosensor-based screening strategy and a specifically designed fragment library. The interaction between fragments and three variants of the target and a reference protein with an active-site zinc ion was measured continuously by surface plasmon resonance. The developed experimental design overcame the inherent instability of MMP-12 and allowed the identification of fragments that interacted specifically with the active-site of MMP-12 but not with the reference protein. The interaction with MMP-12 for selected compounds were analyzed for concentration dependence and saturability. Compounds interacting distinctly with the target were further evaluated by an activity-based assay, verifying MMP-12 inhibition. Two effective inhibitors were identified, and the compound with highest affinity was confirmed to be a competitive inhibitor with an IC50 of 290 nM and a ligand efficiency of 0.7 kcal/mol heavy atom. This procedure integrates selectivity and binding site identification into the screening procedure and does not require structure determination.

[1]  B. G. Rao,et al.  Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.

[2]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[3]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[4]  Sophie Perrier,et al.  Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. , 2004, Journal of molecular biology.

[5]  Walter Huber,et al.  A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.

[6]  Seth M. Cohen,et al.  New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.

[7]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[8]  N. P. Todorov,et al.  Assessment of multiple binding modes in ligand-protein docking. , 2004, Journal of medicinal chemistry.

[9]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[10]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[11]  D. Fattori,et al.  Fragment-based drug design: combining philosophy with technology. , 2007, Current opinion in drug discovery & development.

[12]  Hans Matter,et al.  Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. , 2006, Journal of medicinal chemistry.

[13]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[14]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[15]  U. Danielson,et al.  Characterization of Ca2+ interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation. , 2006, The Biochemical journal.

[16]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[17]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[18]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[19]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[20]  S. Shapiro,et al.  Proteinases in chronic obstructive pulmonary disease. , 2001, Biochemical Society transactions.

[21]  H. Nar,et al.  Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. , 2001, Journal of molecular biology.

[22]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[23]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[24]  R. Huber,et al.  Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. , 2001, Journal of molecular biology.

[25]  B. Samuelsson,et al.  Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors. , 2004, Biochimica et biophysica acta.

[26]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.